person · Reporting owner

Li Yishan

Disclosed activity across 2 companies

Tapewire entity: 25041
SEC CIK: 0001772233

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BlossomHill Therapeutics, Inc.BLSM · Entity 5423	Director · Executive Chairman · 10% owner	August 06, 2026	August 10, 2026
Turning Point Therapeutics, Inc.TPTX · Entity 124461	Director · 10% owner	April 16, 2019	April 16, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BlossomHill Therapeutics, Inc.

Report date August 06, 2026 · Filed August 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Li and Cui Family Trust	1,714,117	Last balance in matching sequence After 2026-08-10 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-08-10 · Conversion · Acquired 1,600,682 · Balance 1,600,682 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Row 2 · 2026-08-10 · Conversion · Acquired 113,435 · Balance 1,714,117 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.
Common StockSEC Table I · non-derivative	IndirectBy RongShan, LLC	124,779	Reported balance After 2026-08-10 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-08-10 · Conversion · Acquired 124,779 · Balance 124,779 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3: The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-08-05	Direct	112,701	Reported balance After 2026-08-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-08-06 · Grant · Acquired 112,701 · Balance 112,701 F4: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.
Series Angel Preferred StockSEC Table II · derivative / convertible security	IndirectBy The Li and Cui Family Trust	0	Reported balance After 2026-08-10 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-08-10 · Conversion · Disposed 1,600,682 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy The Li and Cui Family Trust	0	Reported balance After 2026-08-10 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-08-10 · Conversion · Disposed 113,435 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy RongShan, LLC	0	Reported balance After 2026-08-10 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-08-10 · Conversion · Disposed 124,779 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3: The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	Direct	1,067,121	Reported balance Holding disclosure · report date 2026-08-06 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,067,121
Common StockSEC Table I · non-derivative	IndirectBy Spouse	1,067,121	Reported balance Holding disclosure · report date 2026-08-06 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 1,067,121

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.

F3: The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F4: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.

Turning Point Therapeutics, Inc.

Report date April 16, 2019 · Filed April 16, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,179,219	Reported balance Holding disclosure · report date 2019-04-16 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,179,219
Common StockSEC Table I · non-derivative	IndirectBy spouse	1,301,298	Reported balance Holding disclosure · report date 2019-04-16 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,301,298
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2028-03-08	Direct	Not disclosed	Reported balance Holding disclosure · report date 2019-04-16 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F1: The shares vest in 36 equal successive monthly installments on each monthly anniversary of January 1, 2018.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.12 · Expires 2028-11-05	Direct	Not disclosed	Reported balance Holding disclosure · report date 2019-04-16 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F2: The shares vest in 48 equal successive monthly installments measured from the one month anniversary of September 29, 2018.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2028-03-08	IndirectBy spouse	Not disclosed	Reported balance Holding disclosure · report date 2019-04-16 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F1: The shares vest in 36 equal successive monthly installments on each monthly anniversary of January 1, 2018.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.12 · Expires 2028-11-05	IndirectBy spouse	Not disclosed	Reported balance Holding disclosure · report date 2019-04-16 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F2: The shares vest in 48 equal successive monthly installments measured from the one month anniversary of September 29, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest in 36 equal successive monthly installments on each monthly anniversary of January 1, 2018.

F2: The shares vest in 48 equal successive monthly installments measured from the one month anniversary of September 29, 2018.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 10, 2026 Filed Aug 10, 2026 22:23 UTC	BlossomHill Therapeutics, Inc. BLSM · Entity 5423	ConversionSeries B Preferred Stock · Derivative	124,779	Not disclosed	Not disclosed	Disclosure SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · derivative · entry 9 Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By RongShan, LLC Disclosed balance after: 0 Underlying: Common Stock · 124,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
August 10, 2026 Filed Aug 10, 2026 22:23 UTC	BlossomHill Therapeutics, Inc. BLSM · Entity 5423	ConversionSeries B Preferred Stock · Derivative	113,435	Not disclosed	Not disclosed	Disclosure SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · derivative · entry 8 Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By The Li and Cui Family Trust Disclosed balance after: 0 Underlying: Common Stock · 113,435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Read SEC document
August 10, 2026 Filed Aug 10, 2026 22:23 UTC	BlossomHill Therapeutics, Inc. BLSM · Entity 5423	ConversionSeries Angel Preferred Stock · Derivative	1,600,682	Not disclosed	Not disclosed	Disclosure SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · derivative · entry 7 Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By The Li and Cui Family Trust Disclosed balance after: 0 Underlying: Common Stock · 1,600,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Read SEC document
August 10, 2026 Filed Aug 10, 2026 22:23 UTC	BlossomHill Therapeutics, Inc. BLSM · Entity 5423	ConversionCommon Stock	124,779	Not disclosed	Not disclosed	Disclosure SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · nonDerivative · entry 3 Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By RongShan, LLC Disclosed balance after: 124,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
August 10, 2026 Filed Aug 10, 2026 22:23 UTC	BlossomHill Therapeutics, Inc. BLSM · Entity 5423	ConversionCommon Stock	113,435	Not disclosed	Not disclosed	Disclosure SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · nonDerivative · entry 2 Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By The Li and Cui Family Trust Disclosed balance after: 1,714,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Read SEC document
August 10, 2026 Filed Aug 10, 2026 22:23 UTC	BlossomHill Therapeutics, Inc. BLSM · Entity 5423	ConversionCommon Stock	1,600,682	Not disclosed	Not disclosed	Disclosure SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · nonDerivative · entry 1 Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By The Li and Cui Family Trust Disclosed balance after: 1,600,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Read SEC document
August 06, 2026 Filed Aug 10, 2026 22:23 UTC	BlossomHill Therapeutics, Inc. BLSM · Entity 5423	GrantEmployee Stock Option (Right to Buy) · Derivative	112,701	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001772233-26-000005 · form4-08102026_100812.xml · derivative · entry 6 Li Yishan · CIK 0001772233 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,701 Underlying: Common Stock · 112,701 shares Expires 2036-08-05 F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.